[go: up one dir, main page]

MX2016010295A - Reduccion selectiva de proteinas. - Google Patents

Reduccion selectiva de proteinas.

Info

Publication number
MX2016010295A
MX2016010295A MX2016010295A MX2016010295A MX2016010295A MX 2016010295 A MX2016010295 A MX 2016010295A MX 2016010295 A MX2016010295 A MX 2016010295A MX 2016010295 A MX2016010295 A MX 2016010295A MX 2016010295 A MX2016010295 A MX 2016010295A
Authority
MX
Mexico
Prior art keywords
antibody
engineered cysteine
uncapped
antibody molecules
preparations
Prior art date
Application number
MX2016010295A
Other languages
English (en)
Inventor
L Meyer Damon
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of MX2016010295A publication Critical patent/MX2016010295A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • C07K1/086—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents containing sulfur
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona un método para hacer preparaciones de proteína de cisteína no coronada, que incluye las preparaciones del anticuerpo con cisteína diseñada no coronada. Los métodos incluyen, inter alia, poner en contacto un agente reductor con las moléculas del anticuerpo con cisteína diseñada, cada una de las moléculas del anticuerpo tiene al menos un residuo de cisteína diseñada coronada y al menos un enlace disulfuro intercadena y hacer reaccionar el agente reductor con las moléculas del anticuerpo bajo condiciones suficientes para eliminar la corona de los residuos de cisteína diseñada y formar subproducto coronados. El método también incluye eliminar el subproducto coronado durante la reacción de reducción. Sustancialmente todos los enlaces disulfuro intercadena presentes en las moléculas del anticuerpo antes de la reducción se retienen después de la reducción. Los conjugados de anticuerpo y los métodos para preparar los conjugados de anticuerpo utilizando las preparaciones del anticuerpo no coronado también se describen.
MX2016010295A 2014-02-11 2015-02-11 Reduccion selectiva de proteinas. MX2016010295A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461938378P 2014-02-11 2014-02-11
PCT/US2015/015369 WO2015123265A1 (en) 2014-02-11 2015-02-11 Selective reduction of proteins

Publications (1)

Publication Number Publication Date
MX2016010295A true MX2016010295A (es) 2016-10-17

Family

ID=53800577

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016010295A MX2016010295A (es) 2014-02-11 2015-02-11 Reduccion selectiva de proteinas.
MX2020002791A MX2020002791A (es) 2014-02-11 2016-08-09 Reduccion selectiva de proteinas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020002791A MX2020002791A (es) 2014-02-11 2016-08-09 Reduccion selectiva de proteinas.

Country Status (9)

Country Link
US (3) US10464997B2 (es)
EP (2) EP4190809A1 (es)
JP (4) JP6713931B2 (es)
KR (2) KR102532137B1 (es)
CN (3) CN112979786A (es)
CA (2) CA3211226A1 (es)
HK (1) HK1231400A1 (es)
MX (2) MX2016010295A (es)
WO (1) WO2015123265A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX377339B (es) 2013-08-28 2025-03-06 Abbvie Stemcentrx Llc Metodos de conjugacion de anticuerpos especificos de sitio y composiciones.
US10053511B2 (en) 2013-11-06 2018-08-21 Abbvie Stemcentrx Llc Anti-claudin antibodies and methods of use
PE20160993A1 (es) 2013-12-12 2016-10-14 Abbvie Stemcentrx Llc Nuevos anticuerpos anti-dpep3 y metodos de uso
KR102532137B1 (ko) 2014-02-11 2023-05-12 씨젠 인크. 단백질의 선택적 환원
EP3107576A4 (en) 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anti-dll3 antibodies and drug conjugates for use in melanoma
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
SI3268047T1 (sl) * 2015-03-09 2024-02-29 Heidelberg Pharma Research Gmbh Konjugati amatoksin-protitelo
PL3458100T3 (pl) 2016-02-12 2020-11-30 Byondis B.V. Selektywna redukcja przeciwciał ze zmodyfikowaną cysteiną
US20190127476A1 (en) * 2016-05-06 2019-05-02 Abbvie Stemcentrx Llc Novel anti-tnfrsf21 antibodies and methods of use
US10828375B2 (en) * 2016-11-07 2020-11-10 Seattle Genetics, Inc. Distribution of engineered-cysteine caps
MX2019009372A (es) * 2017-02-08 2019-12-11 Pfizer Produccion a gran escala para cisteinas de anticuerpo protegidas y no protegidas y su uso en la conjugacion de proteinas terapeuticas.
CN107247144B (zh) * 2017-05-16 2019-12-24 上海科华生物工程股份有限公司 一种预处理丙肝抗原的方法和检测试剂盒
US11696958B2 (en) 2017-05-23 2023-07-11 Byondis B.V. Dual conjugation process for preparing antibody-drug conjugates
EP4464719A3 (en) * 2017-08-04 2025-03-05 Amgen Inc. Method of conjugation of cys-mabs
CN107746424A (zh) * 2017-10-30 2018-03-02 上海药明生物技术有限公司 一种IgG4抗体的生物偶联方法
KR102788989B1 (ko) 2019-02-15 2025-03-31 우시 엑스디씨 싱가포르 프라이빗 리미티드 동질성이 개선된 항체-약물 콘쥬게이트의 제조방법
US12109273B2 (en) 2019-02-15 2024-10-08 Wuxi Xdc Singapore Private Limited Process for preparing antibody-drug conjugates with improved homogeneity
CN113189184B (zh) * 2021-04-28 2022-09-09 浙江大学 含有半胱氨酸的毛细管凝胶电泳样品缓冲液
EP4488290A1 (en) * 2022-03-04 2025-01-08 ABTIS Co., Ltd. Method for increasing production yield of antibody-drug conjugate by using thiol-reactive additive
CN114878728A (zh) * 2022-05-06 2022-08-09 浙江大学 一种新型的抗体肽图检测还原方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6111166A (en) 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
GB9422383D0 (en) * 1994-11-05 1995-01-04 Wellcome Found Antibodies
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US20030105017A1 (en) * 2001-07-10 2003-06-05 Gregory Conn Purification of human Troponin I
JP4741838B2 (ja) 2002-07-31 2011-08-10 シアトル ジェネティクス，インコーポレーテッド 癌、自己免疫疾患または感染症を治療するための薬物結合体およびその使用
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
CN104998273A (zh) 2003-11-06 2015-10-28 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
EP3088004B1 (en) 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
CA2605507C (en) 2005-04-19 2016-06-28 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
GB0513852D0 (en) * 2005-07-06 2005-08-10 Celltech R&D Ltd Biological products
CA2614436C (en) 2005-07-07 2016-05-17 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
PT1813614E (pt) 2006-01-25 2012-01-09 Sanofi Sa Agentes citotóxicos compreendendo novos derivados de tomaimicina
WO2008025020A2 (en) 2006-08-25 2008-02-28 Seattle Genetics, Inc. Cd30 binding agents and uses thereof
PT2211904T (pt) 2007-10-19 2016-11-02 Seattle Genetics Inc Agentes de ligação a cd19 e seus usos
ES2613963T3 (es) * 2008-01-18 2017-05-29 Medimmune, Llc Anticuerpos manipulados con cisteína para conjugación específica de sitio
EP2842575B1 (en) 2008-03-18 2017-09-27 Seattle Genetics, Inc. Auristatin drug linker conjugates
CN102365021B (zh) 2009-02-05 2015-07-15 伊缪诺金公司 新型苯并二氮杂*衍生物
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
GB0920127D0 (en) * 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
EP2638066A4 (en) * 2010-11-09 2015-06-03 Medimmune Llc ANTIBODY EQUIPMENT FOR HOMOGENEOUS CONJUGATION
SMT201900181T1 (it) 2011-02-15 2019-05-10 Immunogen Inc Metodi di preparazione di coniugati
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
KR102532137B1 (ko) 2014-02-11 2023-05-12 씨젠 인크. 단백질의 선택적 환원

Also Published As

Publication number Publication date
JP2020143145A (ja) 2020-09-10
US20160347824A1 (en) 2016-12-01
CA3211226A1 (en) 2015-08-20
CN111187348A (zh) 2020-05-22
CN106456725B9 (zh) 2022-08-09
KR20230088389A (ko) 2023-06-19
CN106456725A (zh) 2017-02-22
KR20160136289A (ko) 2016-11-29
JP2017506262A (ja) 2017-03-02
HK1231400A1 (zh) 2017-12-22
US20230391848A1 (en) 2023-12-07
MX2020002791A (es) 2020-07-22
US11667696B2 (en) 2023-06-06
JP2022153663A (ja) 2022-10-12
US20200115438A1 (en) 2020-04-16
JP2025011264A (ja) 2025-01-23
EP3104881A1 (en) 2016-12-21
KR102532137B1 (ko) 2023-05-12
US10464997B2 (en) 2019-11-05
CN106456725B (zh) 2021-03-12
CA2938450A1 (en) 2015-08-20
CN112979786A (zh) 2021-06-18
JP6713931B2 (ja) 2020-06-24
CA2938450C (en) 2023-10-17
EP3104881A4 (en) 2017-09-27
WO2015123265A1 (en) 2015-08-20
EP4190809A1 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
MX2020002791A (es) Reduccion selectiva de proteinas.
MX2023007045A (es) Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) y metodos de uso de los mismos.
MX2022010324A (es) Sitios especificos para modificar anticuerpos para hacer inmunoconjugados.
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
PH12018502400A1 (en) Anti-tim-3 antibodies and methods of use thereof
PH12016501937A1 (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
MX2019012223A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
SA520412669B1 (ar) تصنيع ذيفانات عصبية ناتجة عن معاودة الارتباط الجيني من المطثية الوشيقية
PE20170953A1 (es) ANTICUERPOS ANTI-CD79b Y METODOS DE USO
GEP20237513B (en) Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
MX348071B (es) Variantes de fc.
EP3564259A3 (en) Recognition tags for tgase-mediated conjugation
HK1254313A1 (zh) 作为嵌合抗原受体疗法的t细胞来源的骨髓浸润淋巴细胞
MX364908B (es) Purificación de proteínas usando amortiguador bis-tris.
MX2016011641A (es) Procedimiento de preparacion de proteinas plasmaticas humanas.
EA201691374A1 (ru) Инсулин длительного действия и его применение
MX2015015188A (es) Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab.
PH12017500967A1 (en) Selective reduction of cysteine residues in il-17 antibodies
EA202090560A1 (ru) Способ селективного извлечения элементов халькофильной группы
MD20150109A2 (ro) Construcţii proteice mitocondriale şi utilizările acestora
MX367150B (es) Partículas de rotavirus con proteínas de superficie quiméricas.
PH12016500403A1 (en) An anti serum albumin fab-effector moiety fusion construct, and the preparing method thereof
MY189854A (en) Method for protein purification
PH12020500054A1 (en) Novel therapeutic enzyme fusion protein and use thereof
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof

Legal Events

Date Code Title Description
FG Grant or registration